NASDAQ · Biotechnology · USD
Enlivex Ltd. (ENLV) Stock Analysis
Enlivex Ltd. (ENLV) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
ENLV Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.22
- Previous Close
- $0.22
- Day's Range
- 0.20–0.23
- 52-Week Range
- 0.19–27.15
- Volume
- 738.32K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.41
Valuation
- Market Cap
- $4.03M
- EPS (ttm)Profit attributable to each share over the last twelve months.
- 494.00
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- $1.24B
- Shares Outstanding
- 19.91M
- 1-Year Return
- −98.77%
Dividend and dates
- Avg Volume
- 1.05M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, ENLV closed at $0.20, −98.77% over 1 year.
Enlivex Ltd. (ENLV) has a market capitalization of $4.03M.
In fiscal 2025, ENLV reported revenue of $0.00.
ENLV Stock Return by Calendar Year
Enlivex Ltd. (ENLV) 10-year return: what $10,000 became
- 1 year
- $10,000 $123
- −98.77%
- 5 years
- $10,000 $15
- −99.85%
- 10 years
- $10,000 $2
- −99.98%
If you had invested $10,000 in Enlivex Ltd. (ENLV) 10 years ago, at the close on October 21, 2016, it would have been worth $2 at the close on October 21, 2026: −99.98% in total, −57.06% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −98.08% |
| 2025 | −39.91% |
| 2024 | −56.67% |
| 2023 | −31.44% |
| 2022 | −36.99% |
| 2021 | −25.86% |
| 2020 | +0.46% |
| 2019 | +35.51% |
| 2018 | −66.14% |
| 2017 | −56.04% |
| 2016 (partial year) | −35.80% |
As of October 21, 2026.
ENLV Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | $1.24B | — |
| 2024 | $0.00 | −$15.01M | — |
| 2023 | $0.00 | −$29.07M | — |
| 2022 | $0.00 | −$31.06M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$15.00M | $1.24B | — |
| 2024 | $0.00 | — | −$14.93M | −$15.01M | — |
| 2023 | $0.00 | — | −$25.15M | −$29.07M | — |
| 2022 | $0.00 | — | −$25.80M | −$31.06M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Enlivex Launches Cost Reduction Plan To Prioritize Phase 2b Allocetra Knee Osteoarthritis Trial, Topline Data Expected By Mid-2027
BenzingaEnlivex Ltd. (ENLV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
YahooHC Wainwright & Co. Maintains Buy on Enlivex, Raises Price Target to $80
BenzingaEnlivex Announces Trading Volume On Rain Protocol Reaches $860M
BenzingaEnlivex Announces $400M Private Placement With A Single Institutional Investor Priced At $5.00 Per Share
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B